See more : JCU Corporation (4975.T) Income Statement Analysis – Financial Results
Complete financial analysis of Madrigal Pharmaceuticals, Inc. (MDGL) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Madrigal Pharmaceuticals, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- PTT Exploration and Production Public Company Limited (PEXNY) Income Statement Analysis – Financial Results
- Worthington Industries, Inc. (WOR) Income Statement Analysis – Financial Results
- Gencell Ltd (GNCL.TA) Income Statement Analysis – Financial Results
- Quantum Solar Power Corp. (QSPW) Income Statement Analysis – Financial Results
- Coca-Cola FEMSA, S.A.B. de C.V. (COCSF) Income Statement Analysis – Financial Results
Madrigal Pharmaceuticals, Inc. (MDGL)
About Madrigal Pharmaceuticals, Inc.
Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III clinical trials for the treatment of non-alcoholic steatohepatitis. The company also develops MGL-3745, a backup compound to resmetirom. It has research, development, and commercialization agreement with Hoffmann-La Roche. Madrigal Pharmaceuticals, Inc. is headquartered in West Conshohocken, Pennsylvania.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 147.00K | 7.58M | 14.80M | 144.25M | 2.62M | 743.00K | 0.00 | 0.00 | 173.00K | 1.30M | 0.00 | 0.00 |
| Cost of Revenue | 527.00K | 467.00K | 405.00K | 471.00K | 112.00K | 96.00K | 77.00K | 156.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -527.00K | -467.00K | -405.00K | -471.00K | -112.00K | -96.00K | -77.00K | -156.00 | 0.00 | 0.00 | 0.00 | 147.00K | 7.58M | 14.80M | 144.25M | 2.62M | 743.00K | 0.00 | 0.00 | 173.00K | 1.30M | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 0.00% | 0.00% | 100.00% | 100.00% | 0.00% | 0.00% |
| Research & Development | 272.35M | 245.44M | 205.16M | 184.81M | 72.32M | 25.39M | 24.39M | 15.93M | 54.22M | 68.21M | 71.86M | 49.41M | 41.46M | 40.25M | 51.05M | 81.58M | 52.03M | 50.50M | 59.90M | 38.14M | 24.34M | 7.29M | 277.00K |
| General & Administrative | 108.15M | 48.13M | 37.32M | 21.86M | 22.65M | 15.29M | 7.67M | 9.29M | 13.39M | 15.75M | 15.70M | 11.68M | 11.55M | 11.45M | 12.65M | 14.74M | 14.93M | 8.65M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 108.15M | 48.13M | 37.32M | 21.86M | 22.65M | 15.29M | 7.67M | 9.29M | 13.39M | 15.75M | 15.70M | 11.68M | 11.55M | 11.45M | 12.65M | 14.74M | 14.93M | 8.65M | 11.28M | 7.38M | 5.26M | 0.00 | 124.00K |
| Other Expenses | 0.00 | 0.00 | 273.00K | 100.00K | 0.00 | 200.00K | 350.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.24M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 380.50M | 293.57M | 242.48M | 206.67M | 94.97M | 40.68M | 32.06M | 25.22M | 67.61M | 83.95M | 87.56M | 61.09M | 53.02M | 51.70M | 63.71M | 96.32M | 66.96M | 59.15M | 71.18M | 45.52M | 29.60M | 7.29M | 401.00K |
| Cost & Expenses | 380.50M | 293.57M | 242.48M | 206.67M | 94.97M | 40.68M | 32.06M | 25.22M | 67.61M | 83.95M | 87.56M | 61.09M | 53.02M | 51.70M | 63.71M | 96.32M | 66.96M | 59.15M | 71.18M | 45.52M | 29.60M | 7.29M | 401.00K |
| Interest Income | 19.58M | 2.19M | 363.00K | 4.33M | 11.02M | 7.67M | 558.00K | 48.30K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 96.00K | 1.58M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 12.71M | 3.96M | 0.00 | 0.00 | 11.02M | 7.67M | 558.00K | 1.16M | 1.06M | 2.21M | 2.63M | 1.85M | 1.95M | 569.00K | 312.00K | 489.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 527.00K | 467.00K | 405.00K | 471.00K | 112.00K | 96.00K | 77.00K | 156.00 | 662.00K | 673.00K | 516.00K | 738.00K | 1.46M | 1.93M | 2.46M | 2.72M | 3.35M | 3.66M | 2.46M | 1.55M | 1.01M | 47.06M | 0.00 |
| EBITDA | -379.97M | -293.10M | -242.08M | -206.20M | -94.86M | -40.59M | -31.99M | -22.52M | -3.23M | -83.28M | -87.04M | -60.20M | -43.97M | -34.97M | 81.86M | -90.99M | -62.87M | -53.62M | -71.04M | -43.80M | -27.29M | 10.80M | -401.00K |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -40,954.42% | -579.75% | -236.20% | 58.40% | -3,479.58% | -8,827.19% | 0.00% | 0.00% | -24,977.46% | -2,124.54% | 0.00% | 0.00% |
| Operating Income | -380.50M | -293.57M | -242.48M | -206.67M | -94.97M | -40.68M | -32.06M | -25.22M | -67.61M | -83.95M | -87.56M | -60.94M | -45.43M | -36.90M | 79.30M | -93.71M | -66.22M | -59.15M | -71.18M | -46.93M | -28.29M | -36.26M | -401.00K |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -41,456.46% | -599.05% | -249.26% | 54.98% | -3,583.48% | -8,911.98% | 0.00% | 0.00% | -27,126.59% | -2,169.79% | 0.00% | 0.00% |
| Total Other Income/Expenses | 6.87M | -1.78M | 636.00K | 4.43M | 11.02M | 7.87M | 908.00K | -1.16M | 60.77M | -2.21M | -2.63M | -1.85M | -1.95M | -569.00K | -216.00K | 1.09M | 2.72M | 22.00K | 2.32M | -588.00K | 416.00K | -18.09M | 0.00 |
| Income Before Tax | -373.63M | -295.35M | -241.85M | -202.24M | -83.95M | -32.81M | -31.15M | -26.39M | -68.67M | -86.16M | -90.19M | -62.79M | -47.38M | -37.47M | 79.09M | -92.62M | -122.08M | -59.13M | -68.86M | -47.52M | -27.88M | -54.35M | 0.00 |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -42,714.29% | -624.74% | -253.10% | 54.83% | -3,541.80% | -16,430.69% | 0.00% | 0.00% | -27,466.47% | -2,137.88% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | 3.96M | -768.00K | -4.80M | -11.14M | 7.87M | -635.00K | -373.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.45M | 0.00 | -2.72M | -1.88M | -2.32M | 588.00K | -416.00K | -18.20M | 381.00K |
| Net Income | -373.63M | -299.31M | -241.08M | -197.44M | -72.81M | -32.81M | -31.15M | -26.39M | -68.67M | -86.16M | -90.19M | -62.79M | -47.38M | -37.47M | 79.09M | -92.62M | -63.50M | -57.27M | -68.86M | -45.93M | -27.88M | -36.15M | -381.00K |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -42,714.29% | -624.74% | -253.10% | 54.83% | -3,541.80% | -8,545.76% | 0.00% | 0.00% | -26,551.45% | -2,137.88% | 0.00% | 0.00% |
| EPS | -19.99 | -17.47 | -14.58 | -12.78 | -4.73 | -2.22 | -2.54 | -5.07 | -401.56 | -30.62 | -44.48 | -36.99 | -35.14 | -32.49 | 81.55 | -96.09 | -68.45 | -90.03 | -108.31 | -85.96 | -44.65 | -105.09 | -4.55 |
| EPS Diluted | -19.99 | -17.47 | -14.58 | -12.78 | -4.73 | -2.22 | -2.54 | -5.07 | -401.56 | -30.62 | -44.48 | -36.99 | -35.14 | -32.49 | 81.20 | -96.09 | -68.45 | -90.03 | -108.31 | -85.96 | -44.65 | -105.09 | -4.55 |
| Weighted Avg Shares Out | 18.69M | 17.14M | 16.54M | 15.45M | 15.39M | 14.80M | 12.24M | 5.20M | 171.01K | 2.81M | 2.03M | 1.70M | 1.35M | 1.15M | 968.21K | 963.86K | 927.59K | 636.14K | 635.80K | 534.39K | 624.37K | 344.04K | 83.74K |
| Weighted Avg Shares Out (Dil) | 18.69M | 17.14M | 16.54M | 15.45M | 15.39M | 14.80M | 12.24M | 5.20M | 171.01K | 2.81M | 2.03M | 1.70M | 1.35M | 1.15M | 974.81K | 963.86K | 927.59K | 636.14K | 635.80K | 534.39K | 624.37K | 344.04K | 83.74K |
3 Reasons Why Buying Madrigal Pharmaceuticals Today Is a Wise Move
When a company's shares shoot up 82% in 12 months, investors clearly think it's a good time to be a shareholder -- and that's exactly what's happened to the stock of Madrigal Pharmaceuticals (MDGL 5.53%). Earlier this year, the up-and-coming...
Madrigal (MDGL) Just Flashed Golden Cross Signal: Do You Buy?
Madrigal Pharmaceuticals, Inc. (MDGL) reached a significant support level, and could be a good pick for investors from a technical perspective. Recently, MDGL's 50-day simple moving average broke out above its 200-day moving average; this is known as a "golden...
Wall Street Analysts Believe Madrigal (MDGL) Could Rally 26.44%: Here's is How to Trade
The average of price targets set by Wall Street analysts indicates a potential upside of 26.4% in Madrigal (MDGL). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an...
Zacks Industry Outlook Madrigal, Corcept, Catalyst Larimar and Theravance
Madrigal, Corcept, Catalyst Larimar and Theravance have been highlighted in this Industry Outlook article.
1 Growing Biotech Stock to Buy Today With $1,000 and Hold for 5 Years or More
There's a bright future ahead for this company.
5 Small Drug Stocks to Buy as Trump Gets Re-Elected
Innovation is at its peak for the Zacks Medical-Drugs industry. MDGL, CORT, CPRX, LRMR and TBPH may prove to be good additions to one's portfolio.
Here's Why Madrigal (MDGL) is a Great Momentum Stock to Buy
Does Madrigal (MDGL) have what it takes to be a top stock pick for momentum investors? Let's find out.
Madrigal Pharmaceuticals, Inc. Announces Participation at Three Upcoming Investor Conferences
CONSHOHOCKEN, Pa., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) today announced that the company will participate in fireside chats at three upcoming investor conferences:
Rezdiffra Gains Traction In NASH As Madrigal Pharmaceuticals Targets European Expansion
Madrigal Pharmaceuticals' Rezdiffra has favorable initial market adoption and FDA approval, positioning it as a foundational therapy for NASH with advanced fibrosis. Broad insurance coverage and allowance for non-invasive testing [NIT] enhance patient accessibility and Rezdiffra's adoption rate. Competition from...
Madrigal Q3 Earnings Beat, NASH Drug Sales Drive Top Line, Stock Up
MDGL stock is up as the company reports better-than-expected third-quarter results, beating earnings and revenue estimates, driven by strong Rezdiffra sales.
Source: https://incomestatements.info
Category: Stock Reports